GlassScriptPhysician profile
Leslie A Storey
NPI 1043313133
$10,637.44
in general payments reported to CMS, 2019-2025
33 companies · $1,470 in 2025
The $1,470 reported for 2025 was more than what 83% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,187 · 2020: $527 · 2021: $657 · 2022: $2,154 · 2023: $2,106 · 2024: $2,536 · 2025: $1,470.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,889 · Education: $223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,889.33 |
| Education | $223.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,355.23 | 2019-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $939.60 | 2020-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $785.29 | 2019-2025 | |
| Leo Pharma INC. | $754.87 | 2019-2025 | Adbry |
| Lilly USA, LLC | $754.75 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $613.21 | 2019-2025 | Blu-U, Winlevi |
| Incyte Corporation | $535.11 | 2022-2025 | Opzelura, Iclusig |
| Galderma Laboratories, L.P. | $484.99 | 2019-2025 | Nemluvio, Aklief, Epsolay |
| Genzyme Corporation | $460.39 | 2019-2025 | |
| Pfizer INC. | $408.62 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $362.02 | 2022-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $326.55 | 2019-2025 | Dupixent |
| Arcutis Biotherapeutics, INC. | $262.61 | 2023-2025 | Zoryve |
| Dermavant Sciences, INC. | $231.70 | 2023-2024 | Vtama |
| Amgen INC. | $185.83 | 2021-2024 | Otezla |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $171.82 | 2020-2024 | Affinity |
| Dusa Pharmaceuticals, INC. | $170.17 | 2019 | |
| Biofrontera INC. | $166.72 | 2019-2025 | Ameluz, Rhodoled Xl, Xepi |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $134.35 | 2019-2024 | Arazlo, Jublia, Cabtreo |
| Ucb, INC. | $96.60 | 2019-2023 | Cimzia |
| Organon LLC | $96.55 | 2025 | Vtama, Nexplanon |
| Genentech USA, INC. | $75.77 | 2019-2020 | |
| Helsinn Therapeutics (U.S.), INC. | $70.48 | 2019-2023 | Valchlor |
| Boston Scientific Corporation | $36.52 | 2024 | Rezum Generator |
| Promius Pharma LLC | $25.84 | 2019 | |
| Vyne Pharmaceuticals INC. | $20.97 | 2020 | |
| Allergan, INC. | $17.83 | 2019 | |
| Almirall LLC | $17.71 | 2019 | |
| Fresenius Kabi USA, LLC | $16.86 | 2024 | Idacio |
| Strata Skin Sciences, INC. | $16.12 | 2025 | Xtrac |
| Epi Health, LLC | $15.11 | 2021 | |
| Verrica Pharmaceuticals INC. | $14.38 | 2024 | Ycanth |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.87 | 2023 | Spevigo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leslie Storey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.